Understanding Statin Non-Adherence:Knowing Which Perceptions and Experiences Matter to Different Patients by Wouters, Hans et al.
  
 University of Groningen
Understanding Statin Non-Adherence
Wouters, Hans; Van Dijk, Liset; Geers, Harm C J; Winters, Nina A; Van Geffen, Erica C G;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Wouters, H., Van Dijk, L., Geers, H. C. J., Winters, N. A., Van Geffen, E. C. G., Stiggelbout, A. M., &
Bouvy, M. L. (2016). Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences
Matter to Different Patients. PLoS ONE, 11(1), [e0146272]. https://doi.org/10.1371/journal.pone.0146272
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Knowing Which Perceptions and Experiences
Matter to Different Patients
HansWouters1*, Liset Van Dijk2, Harm C. J. Geers3, Nina A. Winters3,
Erica C. G. Van Geffen3, Anne M. Stiggelbout4, Marcel L. Bouvy3
1 Department of Pharmacy, Unit of Pharmacotherapy and Pharmaceutical Care, Groningen Research
Institute of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Groningen, Groningen,
The Netherlands, 2 NIVEL, Netherlands Institute for Health Services Research, Utrecht, The Netherlands,
3 Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical
Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands, 4 Department of Medical




Non-adherence to statins is substantial and is associated with numerous perceptions and
experiences. However, time limits in clinical practice constrain in depth explorations of
these perceptions and experiences.
Objectives
To propose and examine a strategy aimed at an efficient assessment of a wide array of per-
ceptions and experiences regarding the efficacy, side effects, and practical problems of
statins. Furthermore, to assess associations between this wide array of experiences and
perceptions and non-adherence and to examine whether patients' 'perceived self-efficacy'
moderated these associations.
Methods
Patients were recruited through community pharmacies. A wide array of specific patient per-
ceptions and experiences was efficiently assessed using the electronic Tailored Medicine
Inventory that allows people to skip irrelevant questions. Adherence was measured through
self-report and pharmacy refill data.
Results
Of the two-hundred twenty-nine patients who participated (mean age 63.9, standard devia-
tion 10.2), 40%-70% doubted the necessity of or lacked knowledge about the efficacy of
statins, 20%-35% of the patients were worried about joint and muscle side effects or had
experienced these, and 23% had encountered practical problems regarding information
about statins, intake of tablets, the package, or the blister. Experiencing more practical
problems was associated with increased unintentional non-adherence (Odds ratio 1.54,
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95%CI:1.13–2.10, P < 0.01), whereas worrying about side effects was associated with
increased intentional non-adherence (Odds ratio 1.90, 95%CI:1.17–3.08, P < 0.01). Higher
'perceived self-efficacy' did not moderate these associations.
Conclusions
Insight into patients' specific barriers with regard to appropriate statin use may reveal per-
sonal reasons for being non-adherent. The Tailored Medicine Inventory is a promising tool
to devise individualized intervention strategies aimed at improving adherence by the clini-
cian-patient alliance.
Introduction
Statins are an effective therapy for the primary and secondary prevention of cardiovascular dis-
ease. [1] At the same time, physicians and pharmacists are faced with the challenge of patient
non-adherence to statin therapy. Not only is non-adherence substantial, as it ranges from 30%-
60% at 6 to 12 months after therapy initiation [1], its causal structure is also likely to be multi-
factorial with different predictors being important for different patients. [2] Adherence
improving interventions should therefore be tailored to individual patients' needs and circum-
stances and require comprehensive insight into various potential barriers to patients' appropri-
ate use of statins. However, time and other constraints in clinical practice pose obstacles for
physicians and pharmacists to understand individual patient barriers.
In this study, we therefore propose and examine a strategy to assess a wide array of patient
specific perceptions and experiences in a manner that is both comprehensive and efficient. Spe-
cifically, we adopted the Tailored Medicine Inventory (TMI) that was previously used to assess
perceptions and experiences with regard to the efficacy, side effects, and practical problems
encountered by patients who were treated with antidepressants [3] and women who were
treated with endocrine therapy for prevention of breast cancer recurrence. [4] By adopting logi-
cal routes, the TMI enables skipping of side effects and practical problems that are not applica-
ble to an individual patient. This enables researchers to include many different potential
predictors of non-adherence while test burden can also be kept at a minimum for patients who
encounter only few problems.
Findings of the TMI about specific perceptions and experiences with regard to statin use are
likely to be complementary to findings from other studies which have adopted a patient-oriented
perspective, but which have focused on more general patient beliefs about statins. [1,5]
Specifically, we examined whether one of such more distal patient beliefs, namely 'perceived
self-efficacy', compensated for the impact of side effects and practical problems and as such
weakened the association of specific adverse perceptions and experiences with non-adherence.
A patient's 'perceived self-efficacy' can be defined as his or her perceived ability or confidence
to execute a particular behavior. In our study, we focused on 'perceived self-efficacy' with
regard to 'learning about' and 'taking of' statins. Higher levels of 'perceived self-efficacy' with
regard to learning about and taking of statins were previously found to be associated with bet-
ter adherence. [6] We therefore hypothesized higher levels of 'perceived self-efficacy' to at least
partially undo the negative impact of adverse experiences on adherence. Finally, we also distin-
guished between 'unintentional non-adherence' due to forgetting, and 'intentional non-adher-
ence' or more conscious unwillingness to take statins.
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For this cross-sectional study, patients were recruited through community pharmacies between
January and August 2012 and were included if they were being, or had been treated with statin
therapy in the year prior to recruitment. For ethical reasons, patients were excluded if they
were likely to suffer from severe or terminal illness, psychotic disorders, and dementia as
inferred from their use of co-medication or at the discretion of the pharmacist e.g. in case of
psychosocial problems. Eligible patients participated through filling out an online question-
naire. To reduce selection bias, face-to-face interviews using the TMI were conducted in the
pharmacy with older people who were less likely to access the online questionnaire and with
patients whose refill histories revealed that they had missed 1 prescriptions in the past year
and who were therefore suspected to be non-adherent. For all patients, refill data were
extracted from the automated dispensing records of the pharmacy. The medical ethical com-
mittee of the Leiden University Medical Center approved the study. All patients who partici-
pated online and in the pharmacy gave informed consent.
Demographic and clinical characteristics
We assessed patients' demographic and clinical characteristics including duration of use. To
distinguish between primary and secondary prevention, we assessed patients' indication for
statin use which included elevated cholesterol levels and/or diabetes versus myocardial infarc-
tion, angina pectoris, transient ischemic attack, stroke and/or intermittent claudication or hav-
ing undergone percutaneous coronary intervention and/or coronary bypass artery grafting.
The Tailored Medicine Inventory
Development of the Tailored Medicine Inventory (TMI) has been described elsewhere. [3,4]
Beliefs about the efficacy of statins were assessed with regard to prophylactic efficacy as well as
experiences regarding knowledge and information about the efficacy (12 statements) [7–12]
(see S1 Appendix). Responses to each of the statements were scored on five-point scales (0,
fully disagree; 4, fully agree). Factor analysis (varimax rotation) and inspection of the item con-
tents revealed 3 dimensions of which 2 had sufficient internal consistency, namely 'knowledge
and information about the efficacy' and 'being convinced of the necessity' (see S1 Appendix).
Worry about side effects was assessed for known side effects of statins including: (a) muscu-
lar and joint pain or cramps, (b) vomiting or feeling nauseous, (d) intestinal complaints, (c)
rash, (d) fatigue and (e) insomnia. [1, 13–14] Experiences with known side effects mentioned
above and less-known side effects were assessed with a comprehensive checklist consisting of
classes of side effects with regard to: (a) memory and concentration, [15–16] (b) emotional
problems, [10, 15–18] (c) additional skin and hair problems, [18–20] (d) heart and veins,
[15,17,20] (e) bladder, [18, 20] (f) gynecologic and sexual complaints (in women), [10–11,15,
17–18] (g) male sexual problems, [14, 20] (h) additional stomach problems, [15–17, 20] and (i)
additional muscle complaints. [1]
To avoid test burden, experiences with regard to side effects were efficiently assessed in a
three step manner enabled by logical routes (see Fig 1 for an illustration). First, patients had to
indicate which class(es) of side effects they had experienced. To avoid reporting bias, the
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specific side effects belonging to a class were displayed in parentheses behind that class. Subse-
quently, for each endorsed class of side effects, patients had to indicate which specific side
effect(s) they had experienced. Finally, only for the side effect(s) experienced, patients had to
indicate the level of bother. Worries about side effects were also efficiently assessed but in a two
step manner adopting steps 2 and 3 of the approach shown in Fig 1. Level of worrying and
bother were assessed on five point scales (1, not bothersome/some worry; 5, very bothersome/
very worried).
Practical problems of statin use were also assessed in the same tailored manner in which
experiences with side effects were assessed. The comprehensive checklist of practical problems
consisted of specific problems with regard to (a) (written) information, [6,17 21– 23] (b) logis-
tical problems such as availability and getting refills, [11,24] (c) dosage and intake,
[10,16,22,25] (d) packaging, [11,22, 24] and (e) other problems. [1] Here too, level of bother
was assessed on a five point scale (1, not bothersome; 5, very bothersome).
Perceived Self-efficacy
´Perceived self-efficacy´ with regard to 'learning about' and 'taking of' statins was assessed with
the 8-item Medication Understanding and Use Self-efficacy (MUSE) scale. [6] Internal consis-
tencies (alphas) were 0.85 for the previously reported dimension of ´perceived self-efficacy´
with regard to 'learning about' statins (4 items, scoring range 0–12) and 0.80 for 'taking of' stat-
ins (4 items, scoring range 2–12).
Therapy Adherence
Non-adherence was assessed in the way as described elsewhere. [3] Self-reported non-adher-
ence was assessed with the items from the Medication Adherence Rating Scale (MARS) [26]
and the new Morisky Medication Adherence Scale (MMAS), [27] as well as additional items
about forgetting to take statin tablets and persistence of taking statins. Factor analysis (varimax
Fig 1. Example of tailored examination with the TMI.
doi:10.1371/journal.pone.0146272.g001
Statin Non-Adherence from a Patient Perspective
PLOS ONE | DOI:10.1371/journal.pone.0146272 January 25, 2016 4 / 12
rotation), internal consistency measures, and inspection of the item contents supported the
notion that the items measured 'unintentional non-adherence' due to forgetfulness and 'inten-
tional non-adherence' or more deliberate non-adherence as underlying dimensions. Accord-
ingly, for every patient, (un)intentional non-adherence total scores were calculated by
summating the items measuring (un)intentional non-adherence (See S2 Appendix).
In addition, non-adherence was inferred from the pharmacy refill data. To that end, a Medi-
cation Possession Ratio (MPR) was calculated using information on statin dispensing data
prior to the date on which patients were recruited for the study. We followed the methodology
previously described by Gardarsdottir et al. [28] So-called 'treatment episodes' were calculated
by allowing 90-day gaps between the theoretical end date of a statin prescription and a succes-
sive statin prescription. Where the dispensing date of the successive statin prescription pre-
ceded the theoretical end date of the prior prescription, this overlap was accounted for. For
each patient, the MPR was calculated for the last treatment episode prior to recruitment.
Statistical Analysis
Perceptions and experiences were summarized by means of descriptive statistics. The total
scores of unintentional and intentional non-adherence were found to be skewed, and were
therefore dichotomized at<80% versus80% of the score distribution (unintentional non-
adherence, score of 0 vs.1; intentional non-adherence, score of1 vs.2). Likewise, the
MPR was dichotomized (adherence 80% vs. non-adherence< 80%). Associations of non-
adherence with patient perceptions and experiences were examined with logistic regression
analysis. First, we conducted a series of univariate logistic regression analyses in which we
included demographic and clinical characteristics, mode of participation (online vs. face-to-
face interview), the extent of patients' knowledge about the efficacy and the extent to which
they were convinced of the efficacy, the number of side effects patients were worried about or
had experienced, the number of experienced practical problems as well as 'perceived self-effi-
cacy'. Variables which had a univariate association with non-adherence (P< 0.10) were subse-
quently entered as independent variables into three multivariate logistic regression models
with self-reported intentional and unintentional non-adherence, as well as the MPR calculated
from the pharmacy refill data as the dependent variables. For each significant independent var-
iable reflecting patient experiences and perceptions, we included an interaction term between
that variable and 'perceived self-efficacy' with regard to 'learning about' and 'taking of' statins.
All analyses were done with SPSS version 20 (See S3 Appendix for Dataset).
Results
A total of 229 patients participated. Of them, 41 (18%) participated through a face-to-face
interview. Table 1 presents the demographic and clinical characteristics of the patients.
Contrasting patients who (fully) disagreed with or were neutral (score 2 on 5-point scale)
versus those patients who (fully) agreed (score3 on 5-point scale) with various statements
about the efficacy showed that substantial numbers of patients did not believe the use of statins
to be necessary (N = 92, 40%), were not convinced of (N = 109, 48%) or doubted the efficacy
(N = 108, 47%), did not believe statins to prevent (recurrence of) cardiovascular disease
(N = 112, 49%) or thought the efficacy to be limited (N = 163, 71%). Although 194 (85%)
patients reported that they knew why they needed to use statins, 131 (57%) patients did not
know how statins worked, 116 (51%) patients lacked information thereof, and 101 (44%)
patients did not know to what extent statins reduced the risk of heart disease, but 99 (43%) also
disagreed with the statement that "You have to believe that statins work, otherwise you might
just as well not use them".
Statin Non-Adherence from a Patient Perspective
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Table 2 presents the side effects associated with statins (both worry and experience assessed)
and other side effects (only experience assessed). Over a quarter to a third of patients expressed
worry about ache, stiffness, swelling or inflammation of joints, and muscular pain or muscle
cramps. Fewer patients worried about intestinal complaints, fatigue and insomnia and few
patients worried about vomiting or feeling nauseous and rash (see Table 2). The mean level of




n (%) men 146 (64)
mean age (SD) in years 63.9 (10.2)
n (%) married or living together 185 (81)
n (%) higher educated (vs. low to intermediate) * 105 (46)
Clinical Characteristics
Status of statin use
n (%) starters (< 3 months) 21 (9)
n (%) users (> 3 months) 189 (83)
n (%) discontinued 19 (8)
Duration of use
Users
n (%) 0–1 years 23 (12)
n (%) 1–4 years 64 (34)
n (%) 4 years or longer 102 (54)
Discontinued
n (%) 0–1 years 6 (32)
n (%) 1–4 years 8 (42)
n (%) 4 years or longer 5 (26)
Name of statin treatment
n (%) Atorvastatin 41 (18)
n (%) Fluvastatin 2 (1)
n (%) Pravastatin 19 (8)
n (%) Rosuvastatin 27 (12)
n (%) Simvastatin 140 (61)
Primary vs. Secondary Prevention **
Primary Prevention
n (%) elevated cholesterol 117 (51)
n (%) diabetes 37 (16)
Secondary Prevention
n (%) MI/AP/ TIA/Stroke/ IC 81 (35)
n (%) PCI 31 (14)
n (%) CBAG 12 (5)
* originally scored on an 8-point scale (1, elementary education; 8, university) and dichotomized  4 (low
to intermediate educational level) vs.  5 (higher educational level).
** total sum of reported percentages exceeds 100%, because patients could have >1 indication.
Abbreviations: MI, Myocardial Infarction; AP, Angina Pectoris; TIA, Transient Ischemic Attack; IC,
Intermittent Claudication, PCI, Percutaneous Coronary Intervention; CBAG, Coronary Bypass Artery
Grafting.
doi:10.1371/journal.pone.0146272.t001
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Table 2. Worry about and experience of side effects associated with statin use.
Side Effects
Worry Experience
Yes n (%) M level (SD) Yes n (%) M level (SD)
Side effects associated with statins
Ache, stiffness, swelling joints 62 (27) 3.6 (1.4) 46 (20) 4.6 (0.6)
Muscular pain or muscle cramps 80 (35) 3.7 (1.4) 56 (25) 4.6 (0.8)
Vomiting or feeling nauseous 6 (3) 3.7 (0.8) 3 (1) 3.7 (1.2)
Intestine complaints 35 (15) 3.3 (1.4) 20 (9) 4.8 (0.4)
Rash 19 (8) 3.1 (1.2) 14 (6) 4.1 (1.0)
Fatigue 34 (15) 2.9 (1.2) 18 (8) 4.5 (0.7)
Insomnia 33 (14) 3.2 (1.4) 26 (11) 4.4 (0.9)
Other side effects
Memory, concentration or tiredness
Sleepiness or drowsiness 7 (3) 4.7 (0.8)
Forgetfulness 14 (6) 4.5 (0.8)
Diminished concentration 15 (7) 4.7 (0.6)
Gynecological complaints
Painful or sensitive breasts 3 (1) 4.0 (1.0)
Vaginal discharge, dryness or itch 3 (1) 3.7 (1.5)
Hot ﬂashes 6 (3) 3.7 (1.2)
Decreased libido 8 (4) 3.5 (1.2)
Male sexual problems
Decreased ejaculation 16 (7) 3.4 (1.5)
Decreased erection 27 (12) 4.1 (1.3)
Decrease libido 13 (6) 3.9 (1.3)
Mood
Feeling restless 11 (5) 4.2 (0.9)
Emotional bluntness 5 (2) 4.0 (0.7)
Gloomy mood 9 (4) 4.1 (1.0)
Anxiety, panic or insecurity 7 (3) 4.7 (0.8)
Skin or hair
Hair loss 8 (4) 3.5 (1.1)
Sweating 16 (7) 4.1 (1.0)
Heart, vessels or bladder
Heart palpitations 6 (3) 4.7 (0.8)
Orthostatic hypotension 10 (4) 3.7 (1.3)
Edema 14 (6) 3.8 (1.4)
Urinary retention 4 (2) 3.8 (1.0)
Incontinence 13 (6) 4.2 (1.2)
Mouth, stomach or intestines
Ache, cramps, heartburn or bloating 16 (7) 4.6 (0.9)
Dry mouth 31 (14) 3.8 (1.2)
Muscles, bones or joints
Trembling 3 (1) 3.0 (1.7)
Backache 28 (12) 4.5 (0.6)
doi:10.1371/journal.pone.0146272.t002
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worry was on average moderate to high. No clear differences in mean levels of evoked worry
were observed for the various side effects. At the same time, individual differences in evoked
worry were observed. A fifth of the patients had experienced well-known side effects of statins
including ache, stiffness, swelling or inflammation of joints and muscular pain or muscle
cramps (see Table 2). Some less-known side effects of statins that were frequently experienced
included decreased erection (in males), a dry mouth, and backache. The mean level of bother
was on average moderate to high.
Eighty-seven patients (38%) had experienced one or more practical problems. The most fre-
quently experienced practical problems were those with regard to information, intake of tab-
lets, and package (N = 53, 23%) and limitations in daily life (N = 35, 15%). Logistical problems
such as getting insufficient statin tablets (N = 17, 7%) and concerns about medication interac-
tions were less often reported (N = 27, 12%). On average, practical problems posed moderate
hindrance to patients (mean level of hindrance varying from 2.5–3.5). Again, variation in level
of hindrance between patients was observed (standard deviations of hindrance levels varying
from 1.1–1.3). The mean score of 'perceived self-efficacy' with regard to 'learning about' statins
was 10.0 (standard deviation 2.5) and with regard to 'taking of' statins it was 10.9 (standard
deviation 1.9).
Turning to non-adherence, the likelihood of unintentional non-adherence was increased by
1.5 fold for each experienced practical problem. The likelihood of intentional non-adherence
was increased by 1.9 fold for each additional side effect worried about. Higher 'perceived self-
efficacy' with regard to ' taking statins' was associated with both a decreased likelihood of unin-
tentional and intentional non-adherence (See Table 3). However, 'perceived self-efficacy' did
Table 3. Multivariate Logistic Regression: Prediction of self-reported unintentional and intentional non-adherence and non-adherencemeasured
with the Medication Possession Ratio by patients' perceptions and experiences.
Self-reported Non-adherence Reﬁll Non-adherence
Predictors Unintentional a Intentional b MPR c
Odds ratio (95%CI) Odds ratio (95%CI) Odds ratio (95%CI)
Age 0.98 (0.94–1.02)
Duration of use 0.58 (0.34–0.98)* 1.91 (0.92–3.94)
Primary vs. secondary prevention
Primary prevention Reference Category
Secondary prevention 0.44 (0.17–1.10)
Efﬁcacy:
Being convinced of necessity 0.93 (0.80–1.08) 0.88 (0.74–1.04)
Side effects:
Number of side effects worried about 1.90 (1.17–3.08) †
Number of side effects experienced 0.94 (0.71–1.23)
Practical problems:
Number of practical problems 1.54 (1.13–2.10) †
Learning 'perceived self-efﬁcacy' (MUSE) 1.06 (0.87–1.30)
Taking 'perceived self-efﬁcacy' (MUSE) 0.55 (0.42–0.73) † 0.76 (0.62–0.92) † 0.85 (0.69–1.05)
Patients included in the analysis:
a & b: N = 192;
c: N = 190
* P < 0.05;
† P < 0.01; MPR, Medication Possession Ratio; CI, Conﬁdence Interval; MUSE, Medication Understanding and Use Self-efﬁcacy Scale.
doi:10.1371/journal.pone.0146272.t003
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not weaken the aforementioned associations between non-adherence and negative perceptions
and experiences (results not shown). No associations were found between patient perceptions
and experiences with the MPR calculated from the pharmacy refill data.
Discussion
Overall, our findings showed that a substantial number of patients faced a wide array of specific
barriers to appropriate statin use. Many patients doubted the necessity of statins and lacked
information about and knowledge of the efficacy of statins. There was often worry about and
experience of side effects, in particular the known muscle and joint side effects but also less-
known side effects such as decreased erection (in males), a dry mouth, and backache. Worry
about side effects was found to be associated with increased intentional non-adherence. Practi-
cal problems were also experienced and were associated with increased unintentional non-
adherence.
Contrary to our prediction, 'perceived self-efficacy' did not moderate, or specifically weaken,
the associations between non-adherence and negative perceptions and experiences regarding
the efficacy, the side effects, and the practical problems. This finding is consistent with our pre-
vious findings in patients treated with antidepressants [3] and women treated with endocrine
therapy for prevention of breast cancer recurrence. [4]
Generally, our findings were consistent with previous findings yet also expand these in sev-
eral regards and point to fruitful avenues for further research as well. First, our study of specific
barriers can be considered to be complementary to previous studies conducted in various
patient groups which adopted a patient oriented perspective but which addressed general
beliefs and characteristics. [5,9,10] Second, given that we found a positive association between
worry about side effects and intentional non-adherence and that less-known side effects of stat-
ins were also reported occasionally, assessments of side effects which are typically aimed at
actual experience of known side effects of statins [1, 12, 13] should be expanded with both
worry about side effects and less obvious side effects. Third, practical problems deserve also
further attention as these were associated with unintentional non-adherence. Although several
studies addressed practical problems, these were limited to specific ones. [1,23,24] A more
comprehensive list of practical problems, such as the one we examined, is therefore
recommended.
Our findings underline the potential of the TMI as an impetus to improving the communi-
cation about appropriate use of statins and adherence between clinicians and patients. Because
the TMI assesses a wide range of potential problems from the patient perspective, it is likely to
prevent patronizing of patients. [16] Furthermore, as the TMI is web-based, it can be easily
filled out by a patient prior to the consultation with a physician or pharmacist. Alternatively, it
could be adopted for use in the waiting room. Further implementation research must be con-
ducted to reveal how much shortening and simplification of the TMI is needed and how the
TMI should be applied in clinical practice. A next logical step would be to let clinicians and
patients formulate practical solutions to problems revealed by the TMI. The TMI can aid clini-
cians in tailoring adherence improving interventions to the needs of individual patients. Some
patients might need support in coping with worry about or experience of side effects or practi-
cal problems. Other patients could benefit from additional education about the efficacy of stat-
ins. [29] Indeed, a more subtle problem unraveled by the TMI was the finding on the one hand
that the majority of patients indicated that they knew why they needed to use statins, while on
the other hand substantially less people knew how statins worked, lacked information thereof,
or did not know to what extent statins reduced the risk of heart disease. [30] In future, such
individually tailored interventions might reduce the substantial non-adherence to statins [1].
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This study had several strengths. A key strength was the use of the TMI. Because the TMI
skips irrelevant items, it enables assessing a wide array of perceptions and experiences in a
manner that is both comprehensive and efficient. The TMI thereby reduces the chance of over-
looking crucial perceptions and experiences. Because the causal structure of non-adherence
seems to be multifaceted [2] in the sense that different negative perceptions and/or experiences
may explain non-adherence for different patients, assessing the wide array of perceptions and
experiences seems unavoidable. At the same time, the TMI is likely to prevent question burden
in patients who do not have experienced many side effects or practical problems. A specific
strength with regard to the assessment of side effects was the use of a comprehensive checklist.
We believe that for the understanding of adherence from the perspective of patients, it is not
relevant to distinguish between 'true' side effects that can be traced back to the pharmacody-
namic mechanisms through which statins exert their effects and 'false' side effects reflecting
unrelated symptoms. After all, adherence behavior is likely to be governed by what patients
believe, regardless of whether this is 'true' or 'false'. Moreover, unlikely side effects could also
reflect unknown side effects or unexpected reactions of the body to statins. Finally, in line with
previous recommendations, [2] a strength with regard to the assessment of adherence was that
we adopted both self-reported adherence and adherence as inferred from pharmacy refill data.
While self-reported adherence is believed to be liable to social desirability bias, it allows to dis-
tinguish between non-adherence of a more unintentional and intentional nature. Although
pharmacy refill data are likely to be a more objective measurement of adherence, such a distinc-
tion is not rendered easily thereby making adherence inferred from pharmacy refill data a
more crude overall adherence measure that reflects both unintentional and intentional non-
adherence. The fact that differential associations were observed between patient perceptions
and experiences with self-reported unintentional and intentional non-adherence, but no asso-
ciations were found with adherence inferred from pharmacy refill data, are also interesting in
this regard. They actually contradict the liability of self-reported non-adherence to social desir-
ability bias and at the same time are actually in favor of the idea that adherence measured from
pharmacy refill data constitute a crude measurement. Clearly more research about this matter
is warranted.
Several limitations of this study deserve to be mentioned as well. First, we relied on self-
report to assess clinical characteristics and the findings could be liable to recall bias. However,
as discussed in the previous paragraph, this may be less of a problem for self-reported adher-
ence than mainstream paradigms suggest. Second, although we could infer non-adherence
from refill data, we had no medical data of patients. Therefore, we could not assess to what
extent non-adherence reflected non-acceptance on legitimate grounds e.g. a very low prophy-
lactic efficacy for a particular patient coupled with severe muscle side effects and other impair-
ments in everyday life. Third, our cross-sectional study design precluded an examination of
incident non-adherence and non-persistence and changes in perceptions and experiences over
time. Examination of a wide array of perceptions and experiences in longitudinal studies that
also enroll a greater number of patients who initiate statin therapy is therefore recommended.
Fourth, because of patient anonymity issues and because patients were only informed by mail
about the study, we decided not to record non-response. Although response bias may have
played a role, we deemed it not to be a key concern because our objective was not to estimate
the prevalence of patients' perceptions and experiences regarding the efficacy, side effects and
practical problems and we also observed ample variance in demographic and clinical
characteristics.
Taken together, we conclude that insight with the TMI into patients' specific barriers with
regard to appropriate statin use, is likely to reveal personal reasons for non-adherence that may
be dealt with by the clinician-patient alliance to overcome non-adherence.
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